4-n-Propylamino-6,7-dimethoxychinazolin | 21575-16-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-n-Propylamino-6,7-dimethoxychinazolin
• 英文别名: (6,7-dimethoxy-quinazolin-4-yl)-propyl-amine；6,7-dimethoxy-N-propylquinazolin-4-amine
• CAS: 21575-16-6
• 化学式: C₁₃H₁₇N₃O₂
• 分子量: 247.297
• InChiKey: NDIGIWNPSKZIQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  56.3
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS DE QUINOLÉINE ET DE QUINAZOLINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：STINGRAY THERAPEUTICS INC

  公开号：WO2020190912A1

  公开（公告）日：2020-09-24

  Compounds and methods for their preparation and use as therapeutic or prophylactic agents, fo example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase- 1 (ENPP1).

  化合物及其制备和用作治疗或预防剂的方法，例如通过靶向Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1)来治疗癌症、细菌或病毒性疾病。
• NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT
  申请人：Konkanchi Durga Prasad

  公开号：US20100261740A1

  公开（公告）日：2010-10-14

  The invention relates to substituted 4-(tetrazol-5-yl)-quinazoline derivatives of the formula-I, or pharmaceutically-acceptable salts thereof, which possess anti-proliferative activity such as anti-cancer activity and are accordingly useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of substituted 4-(tetrazol-5-yl)-quinazoline derivatives, to pharmaceutical compositions containing the compound and to its use in the manufacture of medicaments for the production of an anti-proliferative effect in a warm-blooded animal such as man.

  本发明涉及式-I的取代4-(四唑-5-基)-喹唑啉衍生物或其药学上可接受的盐，其具有抗增殖活性，如抗癌活性，并因此在治疗人或动物体的方法中有用。本发明还涉及制造取代4-(四唑-5-基)-喹唑啉衍生物的过程，含有该化合物的药物组合物，以及其用于制造用于在温血动物（如人）中产生抗增殖效应的药物的用途。
• [EN] PHOSPHONATES AS INHIBITORS OF ENPP1 AND CDNP<br/>[FR] PHOSPHONATES EN TANT QU'INHIBITEURS D'ENPP1 ET CDNP
  申请人：STINGRAY THERAPEUTICS INC

  公开号：WO2022125613A1

  公开（公告）日：2022-06-16

  Compounds having activity as inhibitors of ENPP1, CdnP, or both are provided herein. Some embodiments provide compounds having one of the following Structures (I) or (II): or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, wherein R1, R2, R3, R4, R5, R6, R7a, R7b, R7b, R7c, R25, R26, R27a, R27b, R27c, L1, L5, L6, G1, G2, G3and G6are as defined herein. This disclosure provides methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating disorders associated with ENPP1, including uncontrolled cellular proliferation, cancer and virial or bacterial infections in a mammal.

  本文提供具有ENPP1、CdnP或两者抑制剂活性的化合物。其中一些实施例提供具有以下结构之一的化合物(I)或(II)，或其药学上可接受的盐、互变异构体、立体异构体或前药，其中R1、R2、R3、R4、R5、R6、R7a、R7b、R7b、R7c、R25、R26、R27a、R27b、R27c、L1、L5、L6、G1、G2、G3和G6如本文所定义。本文提供了与制备和使用此类化合物相关的方法、包含此类化合物的药物组合物以及用于治疗与ENPP1相关的疾病的方法，包括哺乳动物中的未受控制的细胞增殖、癌症和病毒或细菌感染。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS DE L'HISTONE-DEACETYLASE
  申请人：METHYLGENE INC

  公开号：WO2003024448A2

  公开（公告）日：2003-03-27

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds e.g. (1) and methods for inhibiting deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. (formula 1). All definitions are as the application.
• [EN] NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENTS<br/>[FR] NOUVEAUX DÉRIVÉS DE LA 4-(TÉTRAZOL-5-YL)-QUINAZOLINE EN TANT QU'AGENTS ANTI-CANCÉREUX
  申请人：NATCO PHARMA LTD

  公开号：WO2009057139A2

  公开（公告）日：2009-05-07

  The invention relates to substituted 4-(tetrazol-5-yl)-quinazoline derivatives of the formula-I, or pharmaceutically-acceptable salts thereof, which possess anti-proliferative activity such as anti-cancer activity and are accordingly useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of substituted 4-(tetrazol-5-yl)-quinazoline derivatives, to pharmaceutical compositions containing the compound and to its use in the manufacture of medicaments for the production of an anti-proliferative effect in a warm-blooded animal such as man.